Tislelizumab, a monoclonal antibody with high binding affinity to thePD-1receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lungcancer^[1].

Liquid

1858168-59-8

Please store the product under the recommended conditions in the Certificate of Analysis.